Dr Renée Hoenderkamp is concerned about so-called ‘miracle’ slimming jabs that are said to cut the risk of heart attack.

She joined Bev Turner and Andrew Pierce on GB News to claim the drug has alarming side effects that Britons should be wary of.

She also urged those considering using a slimming jab like Ozempic or Wegovy to take personal responsibility and cut fat in a natural manner, as such treatment may not end up having the desired effect.

“There is no long term data on this particular drug and there are some pretty horrible side effects”, she warned.

“About one in 100 people will get Pancreatitis. When you get this, your risk of pancreatic cancer is increased for about three years after the event.

“Pancreatic cancer is very expensive to the NHS and also kills you very quickly because it’s very silent.

LATEST DEVELOPMENTS

'I'm a longevity researcher and I swear by this diet to reverse the ageing process and live longer'
Miracle anti-obesity jab found to cut heart attack risk by 20% and maintain weight loss for years
Super supplement found to boost working memory and attention after a single dose

“About one in 100 people will get pancreatitis. When you get this, your risk of pancreatic cancer is increased for about three years after the event.

“Pancreatic cancer is very expensive to the NHS and also kills you very quickly because it’s very silent.

“A lot of people get hair loss, there is also reports of psychosis so it’s affecting mood. There are people that are losing so much weight that they’re losing muscle mass.

“There are so many side effects that we just don’t know about and how they will play out in the long term.

“Let’s not forget, every single person on this trial was over the age of 45 and already obese or overweight. If they had not got to that point, they wouldn’t have any of these things that the NHS are now dealing with.”

A study showing the drug helps cut the risk of heart attack was branded “completely flawed” by Hoenderkamp as she continued to criticise the development.

“You have to ask yourself, who are the people that have gone on to have heart attacks or strokes from this study?”, she asked.

“This data is paid for by the drug company. You’re not allowed to look at it. There were a lot of people who couldn’t continue with this trial.

“But you have every single front page of the newspapers telling people they’re going to avoid heart attacks and diabetes if they take this drug for life.

“It’s a collusion between Big Pharma and the media to sell this to the public.”

The drugs have been hailed as having a “potentially very important place in treatment” with “wide-scale opportunity” by lead researcher Professor John Deanfield from University College London (UCL).

Data was collected from the Select trial, which was conducted by semaglutide manufacturer Novo Nordisk to explore if the drug, which is sold under the brand names Wegovy, Ozempic and Rybelsus, could reduce the risk of heart attacks or stroke in obese people without diabetes.

The five-year study comprised 17,604 adults over the age of 45 from 41 countries and explored the amount of time before patients suffered major cardiovascular events.

The trial was hailed as a “game-changer” by Deanfield.

He told the Telegraph: “In the 1990s when statins came in, we finally figured out that there was a class of drugs that would change the biology of this disease.

“That was a major breakthrough to transform cardiology practice. We now have a class of drugs that could equally transform many chronic diseases of ageing.”